TELA Bio Dirección

Dirección controles de criterios 2/4

El CEO de TELA Bio's es Antony Koblish , nombrado en Apr 2012, tiene una permanencia de 12.08 años. compensación anual total es $2.37M, compuesta por 25.2% salario y 74.8% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.87% de las acciones de la empresa, por valor de $960.80K. La antigüedad media del equipo directivo y de la junta directiva es de 2.7 años y 5 años, respectivamente.

Información clave

Antony Koblish

Chief Executive Officer (CEO)

US$2.4m

Compensación total

Porcentaje del salario del CEO	25.2%
Permanencia del CEO	12.1yrs
Participación del CEO	0.9%
Permanencia media de la dirección	2.7yrs
Promedio de permanencia en la Junta Directiva	5yrs

Actualizaciones recientes de la dirección

Recent updates

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

Mar 24

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Oct 02

Tela Bio prices $32M common stock offering

Aug 16

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

May 12

TELA Bio - Follow Up With Management

Jan 14

Our First Look At TELA Bio

Nov 04

TELA Bio Plugging Away

Oct 25

TELA Bio (TELA) Investor Presentation - Slideshow

May 26

Bearish: Analysts Just Cut Their TELA Bio, Inc. (NASDAQ:TELA) Revenue and EPS estimates

Mar 30

Health Check: How Prudently Does TELA Bio (NASDAQ:TELA) Use Debt?

Feb 12

TELA Bio guides Q4 and FY20 revenue below consensus

Jan 14

TELA Bio EPS misses by $0.09, beats on revenue

Nov 11

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Antony Koblish en comparación con los beneficios de TELA Bio?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	US$2m	US$595k	-US$47m
Sep 30 2023	n/a	n/a	-US$44m
Jun 30 2023	n/a	n/a	-US$44m
Mar 31 2023	n/a	n/a	-US$45m
Dec 31 2022	US$2m	US$566k	-US$44m
Sep 30 2022	n/a	n/a	-US$43m
Jun 30 2022	n/a	n/a	-US$40m
Mar 31 2022	n/a	n/a	-US$36m
Dec 31 2021	US$2m	US$538k	-US$33m
Sep 30 2021	n/a	n/a	-US$32m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$30m
Dec 31 2020	US$806k	US$479k	-US$29m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$29m
Dec 31 2019	US$2m	US$403k	-US$30m
Sep 30 2019	n/a	n/a	-US$32m
Jun 30 2019	n/a	n/a	-US$30m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$569k	US$375k	-US$30m

Compensación vs. Mercado: La compensación total de Antony($USD2.37M) está por encima de la media de empresas de tamaño similar en el mercado US ($USD668.06K).

Compensación vs. Ingresos: La compensación de Antony ha aumentado mientras la empresa no es rentable.

CEO

Antony Koblish (57 yo)

12.1yrs

Permanencia

US$2,366,371

Compensación

Mr. Antony Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the President, Director and Chief Executive Officer of TELA Bio, Inc. since April 2012, which he co-founded in April 20...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Antony Koblish	Co-founder	12.1yrs	US$2.37m	0.87% $ 1.0m
Roberto Cuca	CFO & COO	2.7yrs	US$1.06m	0.16% $ 187.1k
Paul Talmo	Chief Technology Officer	no data	US$962.24k	0.12% $ 141.0k
Megan Smeykal	VP, Corporate Controller	3yrs	sin datos	0.033% $ 38.3k
D. Ocasio	General Counsel & Corporate Secretary	2.1yrs	sin datos	sin datos
Jennifer Armstrong	Senior Vice President of Human Resources	2.3yrs	sin datos	sin datos
Gregory Firestone	Chief Business Officer	no data	sin datos	0.21% $ 239.0k
Michael Leonard	Senior Vice President of Technical Operations	2.3yrs	sin datos	sin datos
Peter Murphy	Chief Commercial Officer	4.3yrs	US$936.76k	0.055% $ 64.0k
Louisa Smith	Investor Relations Contact Officer	no data	sin datos	sin datos

2.7yrs

Permanencia media

53yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de TELA se considera experimentado (2.6 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Antony Koblish	Co-founder	12.1yrs	US$2.37m	0.87% $ 1.0m
Vincent Burgess	Independent Director	11.4yrs	US$128.59k	0.032% $ 37.7k
Federica O'Brien	Independent Director	4.5yrs	US$133.59k	0.013% $ 14.8k
Douglas Evans	Independent Chairman of the Board	4.1yrs	US$161.09k	0.013% $ 14.8k
Lisa Colleran	Independent Director	4.1yrs	US$133.59k	0.013% $ 14.8k
Kurt Azarbarzin	Independent Director	5.5yrs	US$121.09k	0.013% $ 14.8k

5.0yrs

Permanencia media

60yo

Promedio de edad

Junta con experiencia: La junta directiva de TELA se considera experimentada (4.9 años de antigüedad promedio).

TELA Bio Dirección

Dirección controles de criterios 2/4

Información clave

Actualizaciones recientes de la dirección

TELA Bio, Inc., Annual General Meeting, Jun 04, 2024

John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc

Insufficient new directors

CFO & COO recently bought US$83k worth of stock

TELA Bio, Inc., Annual General Meeting, Jun 01, 2022

TELA Bio, Inc. Appoints Taylor Ocasio as General Counsel

Recent updates

TELA Bio, Inc. to Report Q1, 2024 Results on May 09, 2024

TELA Bio, Inc., Annual General Meeting, Jun 04, 2024

TELA Bio, Inc. Announces U.S. Commercial Launch of Robotic-Compatible OviTex IHR

Earnings Update: TELA Bio, Inc. (NASDAQ:TELA) Just Reported Its Annual Results And Analysts Are Updating Their Forecasts

TELA Bio, Inc. Announces U.S. Commercial Launch of LIQUIFIX

Full year 2023 earnings released: US$2.04 loss per share (vs US$2.72 loss in FY 2022)

Many Still Looking Away From TELA Bio, Inc. (NASDAQ:TELA)

TELA Bio, Inc. to Report Q4, 2023 Results on Mar 21, 2024

Consensus EPS estimates fall by 215%

TELA Bio, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target decreased by 18% to US$14.40

Third quarter 2023 earnings: EPS and revenues miss analyst expectations

TELA Bio, Inc. to Report Q3, 2023 Results on Nov 09, 2023

TELA Bio (NASDAQ:TELA) Has Debt But No Earnings; Should You Worry?

John Nosenzo Resigns as Member of the Board of Directors of TELA Bio, Inc

TELA Bio, Inc. Announces U.S. Commercial Launch of OviTex PRS Long-Term Resorbable for Plastic and Reconstructive Surgery

Consensus EPS estimates upgraded to US$0.57 loss

Second quarter 2023 earnings: EPS exceeds analyst expectations

TELA Bio, Inc. Reaffirms Revenue Guidance for Full Year 2023

Getting In Cheap On TELA Bio, Inc. (NASDAQ:TELA) Might Be Difficult

TELA Bio, Inc. to Report Q2, 2023 Results on Aug 09, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Tela Bio, Inc. Reaffirms Earnings Guidance for the Full Year 2023

Insufficient new directors

Consensus EPS estimates fall by 13%, revenue upgraded

Full year 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

TELA Bio Announces U.S. Commercial Launch of NIVIS Fibrillar Collagen Pack

Price target decreased to US$17.40

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target decreased to US$17.40

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

TELA Bio, Inc. to Report Q3, 2022 Results on Nov 09, 2022

TELA Bio, Inc. Announces Publication of 24-Month Bravo Study Results Demonstrating Benefits of Ovitex(R) Reinforced Tissue Matrix in Hernia Repair

TELA Bio: Tailwinds In Hernia Repair Market And Promising Clinical Data To Drive Accelerating Adoption

Consensus forecasts updated

TELA Bio, Inc. has completed a Follow-on Equity Offering in the amount of $32 million.

Tela Bio prices $32M common stock offering

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

TELA Bio, Inc. Provides Revenue Guidance for the Full Year 2022

Tela Bio, Inc. Highlights Results from BRAVO and ReBAR Studies on the Benefits of OviTex® Reinforced Tissue Matrix in Hernia Repairs

TELA Bio, Inc. to Report Q2, 2022 Results on Aug 10, 2022

CFO & COO recently bought US$83k worth of stock

TELA Bio, Inc. Provides Revenue Guidance for the Fiscal Year 2022

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Is TELA Bio (NASDAQ:TELA) Using Debt Sensibly?

TELA Bio, Inc. Announces Revenue Guidance for the Full Year 2022

TELA Bio, Inc., Annual General Meeting, Jun 01, 2022

TELA Bio, Inc. Appoints Taylor Ocasio as General Counsel

TELA Bio, Inc. Announces U.S. Commercial Launch of SiteGuard™ No Rinse Antimicrobial Solution

TELA Bio - Follow Up With Management

High number of new directors

Third quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 3Q 2020)

Our First Look At TELA Bio

TELA Bio Plugging Away

TELA Bio® Announces New Data on Use of OviTex in a Range of Hernia Repair Applications, Including Novel ReBAR (Reinforced Biologic Augmented Repair) Technique

Second quarter 2021 earnings released: US$0.57 loss per share (vs US$0.53 loss in 2Q 2020)

TELA Bio, Inc. Provides Earnings Guidance for the Full Year 2021

High number of new directors

TELA Bio, Inc.(NasdaqGM:TELA) dropped from Russell 3000E Index

Independent Director Adele Oliva has left the company

Chief Financial Officer Nora Brennan has left the company

TELA Bio (TELA) Investor Presentation - Slideshow

TELA Bio, Inc. Initiates Bravo II Study of Ovitex for the Robotic Repair of Ventral Hernias

TELA Bio, Inc. Provides Revenue Guidance for the Full Year of 2021

First quarter 2021 earnings released: US$0.56 loss per share (vs US$0.63 loss in 1Q 2020)

Consensus revenue estimates fall to US$28.9m

Bearish: Analysts Just Cut Their TELA Bio, Inc. (NASDAQ:TELA) Revenue and EPS estimates

Full year 2020 earnings released: US$2.23 loss per share (vs US$17.10 loss in FY 2019)

TELA Bio, Inc. Provides Revenue Guidance for the Full Year of Fiscal 2021